Chemie Grünenthal GmbH

Thalidomide became a pharmaceutical-accountability test because a medicine promoted as a sedative and remedy for pregnancy-related discomfort crossed national markets without an evidence system capable of protecting embryonic development; because clinicians' recognition of an unusual malformation pattern had to overcome fragmented reporting, commercial distribution and regulatory differences; and because withdrawal, litigation, compensation and later tightly controlled uses answered different questions rather than producing one global verdict.